PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 1996 August; 40(8): 1914–1918.
PMCID: PMC163439

Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Abstract

An in vitro method of detecting synergy which is simple to perform, accurate, and reproducible and has the potential for clinical extrapolation is desirable. Time-kill and checkerboard methods are the most widely used techniques to assess synergy but are time-consuming and labor-intensive. The Epsilometer test (E test), a less technically demanding test, has not been well studied for synergy testing. We performed synergy testing of Escherichia coli ATCC 35218, Enterobacter cloacae ATCC 23355, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213 with various combinations of cefepime or ceftazidime with tobramycin or ciprofloxacin using time-kill, checkerboard, and E test techniques. Time-kill testing was performed against each organism alone and in combinations at one-fourth times the MIC (1/4 x MIC) and 2 x MIC. With checkerboard tests, the same combinations were studied at concentrations ranging from 1/32 x to 4 x MIC. Standard definitions for synergy, indifference, and antagonism were utilized. E test strips were crossed at a 90 degree angle so the scales met at the MIC of each drug alone, and the fractional inhibitory concentrations index was calculated on the basis of the resultant zone on inhibition. All antimicrobial combinations demonstrated some degree of synergy against the test organisms, and antagonism was infrequent. Agreement with time-kill testing ranged from 44 to 88% and 63 to 75% by the checkerboard and E test synergy methods, respectively. Despite each of these methods utilizing different conditions and endpoints, there was frequent agreement among the methods. Further comparisons of the E test synergy technique with the checkerboard and time-kill methods are warranted.

Full Text

The Full Text of this article is available as a PDF (309K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24(1):45–54. [PubMed]
  • Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Aug;26(2):220–223. [PMC free article] [PubMed]
  • Berenbaum MC. Correlations between methods for measurement of synergy. J Infect Dis. 1980 Sep;142(3):476–480. [PubMed]
  • Berenbaum MC. Synergy assessment with growth curves. J Infect Dis. 1984 Aug;150(2):304–304. [PubMed]
  • Chadwick EG, Shulman ST, Yogev R. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J Infect Dis. 1986 Oct;154(4):670–675. [PubMed]
  • Chan EL, Zabransky RJ. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas. Diagn Microbiol Infect Dis. 1987 Feb;6(2):157–164. [PubMed]
  • De Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):96–100. [PubMed]
  • Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985 May;27(5):679–682. [PMC free article] [PubMed]
  • King TC, Schlessinger D, Krogstad DJ. The assessment of antimicrobial combinations. Rev Infect Dis. 1981 May-Jun;3(3):627–633. [PubMed]
  • Klastersky J, Cappel R, Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972 Dec;2(6):470–475. [PMC free article] [PubMed]
  • Klastersky J, Meunier-Carpentier F, Prevost JM, Staquet M. Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum. J Infect Dis. 1976 Sep;134(3):271–276. [PubMed]
  • Lau WK, Young LS, Black RE, Winston DJ, Linne SR, Weinstein RJ, Hewitt WL. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med. 1977 Jun;62(6):959–966. [PubMed]
  • Lerner SA, Dudek EJ, Boisvert WE, Berndt KD. Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct;6 (Suppl 3):S678–S688. [PubMed]
  • Moellering RC., Jr Antimicrobial synergism--an elusive concept. J Infect Dis. 1979 Oct;140(4):639–641. [PubMed]
  • Moody JA, Gerding DN, Peterson LR. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. Am J Med. 1987 Apr 27;82(4A):44–54. [PubMed]
  • Norden CW, Wentzel H, Keleti E. Comparison of techniques for measurement of in vitro antibiotic synergism. J Infect Dis. 1979 Oct;140(4):629–633. [PubMed]
  • Robinson A, Bartlett RC, Mazens MF. Antimicrobial synergy testing based on antibiotic levels, minimal bactericidal concentration, and serum bactericidal activity. Am J Clin Pathol. 1985 Sep;84(3):328–333. [PubMed]
  • Ryan RW, Kwasnik I, Tilton RC. Methodological variation in antibiotic synergy tests against enterococci. J Clin Microbiol. 1981 Jan;13(1):73–75. [PMC free article] [PubMed]
  • Weinstein AJ, Moellering RC., Jr Penicillin and gentamicin therapy for enterococcal infections. JAMA. 1973 Feb 26;223(9):1030–1032. [PubMed]
  • Weinstein RJ, Young LS, Hewitt WL. Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med. 1975 Nov;86(5):853–862. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)